【摘要】 目的探讨热休克诱导的细胞株负载树突状细胞(DC)治疗晚期非小细胞肺癌的安全性和有效性。方法 38例均接受过常规治疗的晚期非小细胞肺癌患者分成两组,DC治疗组18例,对照组20例。治疗组患者分离患者外周血单核细胞,体外诱导DC,热休克诱导凋亡的细胞株负载自体DC,将DC行皮内回输,观察患者的安全性和有效性,比较两组的总生存期(OS)。结果没有观察到明显的不良反应,DC免疫治疗安全性高;治疗组的中位生存期为9.2月,对照组的中位生存期7.2月,但两组比较没有统计学意义。结论非小细胞肺癌的DC免疫治疗值得进一步研究。更多还原

【Abstract】 Objective Therapeutic outcomes of advanced non-small-cell lung cancer(NSCLC) are not satisfactory,dendritic cells(DCs) vaccine has been developed as a novel strategy against cancer,the aim of this study was to investigate the safty and clinical value of DCs vaccine loaded with heat shock induced apoptotic NSCLC cell lines.Methods A two-armed trial,with 38 patients with stage ⅢB-Ⅳ NSCLC after standard therapy was performed.Peripheral blood mononuclear cells(PBMCs) were separated into adherent cells for induction of DCs loaded with heat shock induced apoptotic NSCLC cell lines.Every week the DCs vaccine was administered intradermally near the inguinal region.The safety and overall survival(OS) were examined.Results DCs vaccine was well tolerated and no obviously toxicity was observed.Although the median survival and the one-year-survival rate of the experiment group were higher than the control group,the statistics showed no significance.Conclusion DCs vaccine for NSCLS is worthy of further study.更多还原